Formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or class II molecules for vaccines

Patent metadata

Field	Value
Publication number	US-9283267-B2
Application number	US-201213346197-A
Country	US
Kind code	B2
Filing date	Jan 9, 2012
Priority date	Apr 24, 2008
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

The present invention relates to novel formulations of tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular glioma, especially glioblastoma cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumor immune responses.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising:
(a) at least 2 peptides; wherein said at least 2 peptides comprise SEQ ID NO: 5 and SEQ ID NO: 13, respectively; each peptide has a length of between 8 and 16 amino acids;
wherein said peptides show a solubility in 90% acetic acid of at least 2.7 mg/mL; and
(b) mannitol and poloxamer 188 or mannitol and polyoxyethylene (20) sorbitan monooleate, wherein the ratio by weight of said peptides to mannitol to poloxamer 188 is in the range including and between 1:5:1.5 to 1:8:2.2 or including and between 1:0:2 to 1:0:2.2; or wherein the ratio by weight of said peptides to mannitol to polyoxyethylene (20) sorbitan monooleate is in the range including and between 1:2:1.5 to 1:8:2.2.

2. The pharmaceutical composition of claim 1 , wherein said ratio by weight of peptides to mannitol to poloxamer 188 is in the range including and between 1:0:2 to 1:0:2.2.

3. The pharmaceutical composition of claim 1 , further comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-4 and 6-10; and comprising mannitol and poloxamer 188, wherein the ratio by weight of peptides to mannitol to poloxamer 188 ranges is in the range including and between 1:5:1.5 to 1:8:2.2 or including and between 1:0:2 to 1:0:2.2 wherein each peptide has a length of between 8 and 16 amino acids.

4. The pharmaceutical composition of claim 3 , wherein the ratio by weight of peptides to mannitol to poloxamer 188 is in the range including and between 1:0:2 to 1:0:2.2.

5. The pharmaceutical composition of claim 1 , further comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-4 and 6-10 and comprising mannitol and polyoxyethylene (20) sorbitan monooleate, wherein the ratio by weight of peptides to mannitol to polyoxyethylene (20) sorbitan monooleate is in the range including and between 1:2:1.5 to 1:8:2.2 wherein each peptide has a length of between 8 and 16 amino acids.

6. The pharmaceutical composition of claim 1 , wherein said composition further comprises at least one peptide having an overall length of between 9 and 16 amino acids.

7. The pharmaceutical composition of claim 1 , wherein at least one of said peptides includes non-peptide bonds.

8. The pharmaceutical composition of claim 1 , wherein said at least 2 peptides present in the composition are tissue, cancer, and/or patient-specific.

9. The pharmaceutical composition of claim 1 , further comprising at least one suitable adjuvant.

10. A kit comprising:
(a) a container containing the pharmaceutical composition of claim 1 , in solution or in lyophilized form;
(b) optionally, a second container containing a diluent or reconstituting solution for said lyophilized formulation and/or at least one adjuvant; and
(c) optionally, instructions for (i) use of the solution of (a), or (ii) reconstitution, and/or use of said lyophilized formulation, and
(d) optionally further comprising one or more of (i) a buffer, (ii) a diluent, (iii) a filter, (iv) a needle, and (v) a syringe.

11. The pharmaceutical composition of claim 2 , wherein at least one of said peptides includes non-peptide bonds.

12. The pharmaceutical composition of claim 1 , wherein said composition further comprises at least one peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2.

13. The pharmaceutical composition of claim 2 , wherein said at least 2 peptides present in the composition are tissue, cancer, and/or patient-specific.

14. The pharmaceutical composition of claim 2 , further comprising at least one suitable adjuvant.

15. A kit comprising:
(a) a container containing a pharmaceutical composition of claim 2 , in solution or in lyophilized form;
(b) optionally, a second container containing a diluent or reconstituting solution for said lyophilized formulation and/or at least one adjuvant; and
(c) optionally, instructions for (i) use of the solution of (a), or (ii) reconstitution, and/or use of said lyophilized formulation.

16. The pharmaceutical composition of claim 1 , wherein said pharmaceutical formulation is stable for two years at −20° C.

17. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a lyophilisate that can be completely dissolved in a 4.2% sodium bicarbonate solution within two minutes or less without the use of an ultrasonic homogenizer, and wherein at least one of the peptides has a solubility in 90% acetic acid of not more than 2.9 mg/mL.

Assignees

• Lewandrowski Peter
• Flohr Christian
• Immatics Biotechnologies Gmbh

Inventors

• Lewandrowski Peter
• Flohr Christian

Classifications

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title